Real-life efficacy and safety of upadacitinib in adolescents with moderate-to-severe atopic dermatitis unresponsive to dupilumab: A case series

被引：7
作者：
Patruno, Cataldo [1 ]
Fabbrocini, Gabriella [2 ]
Potestio, Luca [2 ,4 ]
Genco, Lucia [2 ]
Napolitano, Maddalena [3 ]
机构：
[1] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy
[2] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy
[3] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy
[4] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Via Pansini 5, I-80131 Naples, Italy
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2023年 / 37卷 / 07期
关键词：
DOUBLE-BLIND; PLACEBO; ADULTS;
D O I：
10.1111/jdv.19011
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E901 / E903
页数：3
相关论文
共 11 条
[1]  
[Anonymous], 2021, RINVOQ SUMM PROD CHA
[2]   Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial [J].
Blauvelt, Andrew ;
Teixeira, Henrique D. ;
Simpson, Eric L. ;
Costanzo, Antonio ;
De Bruin-Weller, Marjolein ;
Barbarot, Sebastien ;
Prajapati, Vimal H. ;
Lio, Peter ;
Hu, Xiaofei ;
Wu, Tianshuang ;
Liu, John ;
Ladizinski, Barry ;
Chu, Alvina D. ;
Eyerich, Kilian .
JAMA DERMATOLOGY, 2021, 157 (09) :1047-1055
[3]   Upadacitinib in patients with resistant atopic dermatitis: a retrospective case-series [J].
Dal Bello, G. ;
Schena, D. ;
Girolomoni, G. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (09) :1499-1500
[4]   Real-life experience of upadacitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis - a case series [J].
Feraru, G. ;
Nevet, M. J. ;
Samuelov, L. ;
Hodak, E. ;
Avitan-Hersh, E. ;
Ziv, M. ;
Dodiuk-Gad, R. P. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (10) :E832-E833
[5]   Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials [J].
Guttman-Yassky, Emma ;
Teixeira, Henrique D. ;
Simpson, Eric L. ;
Papp, Kim A. ;
Pangan, Aileen L. ;
Blauvelt, Andrew ;
Thaci, Diamant ;
Chu, Chia-Yu ;
Hong, H. Chih-Ho ;
Katoh, Norito ;
Paller, Amy S. ;
Calimlim, Brian ;
Gu, Yihua ;
Hu, Xiaofei ;
Liu, Meng ;
Yang, Yang ;
Liu, John ;
Tenorio, Allan R. ;
Chu, Alvina D. ;
Irvine, Alan D. .
LANCET, 2021, 397 (10290) :2151-2168
[6]   Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis [J].
Hayama, Koremasa ;
Fujita, Hideki .
DERMATOLOGIC THERAPY, 2022, 35 (07)
[7]   A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up) An interim 24-week analysis [J].
Katoh, Norito ;
Ohya, Yukihiro ;
Murota, Hiroyuki ;
Ikeda, Masanori ;
Hu, Xiaofei ;
Ikeda, Kimitoshi ;
Liu, John ;
Sasaki, Takuya ;
Chu, Alvina D. ;
Teixeira, Henrique D. ;
Saeki, Hidehisa .
JAAD INTERNATIONAL, 2022, 6 :27-36
[8]   Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib [J].
Licata, G. ;
Gambardella, A. ;
Tancredi, V. ;
Calabrese, G. ;
De Rosa, A. ;
Alfano, R. ;
Argenziano, G. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (02) :E150-E152
[9]   Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses [J].
Mohamed, Mohamed-Eslam F. ;
Gopalakrishnan, Sathej ;
Teixeira, Henrique D. ;
Othman, Ahmed A. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (05) :628-635
[10]   Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience [J].
Napolitano, M. ;
Fabbrocini, G. ;
Genco, L. ;
Martora, F. ;
Potestio, L. ;
Patruno, C. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (09) :1497-1498
12